Triple negative breast cancers (TNBC) are heterogeneous and aggressive pathologies,
with distinct morphological and clinical characteristics associated with their genetic diversity, epigenetics,
transcriptional changes and aberrant molecular patterns. Treatment with anti-neoplastic
drugs exerts systemic effects with low specificity, and incipient improvement in overall survival due
to chemoresistance and recurrence. New alternatives for TNBC treatment are urgent and parthenolide
or its analogues have been explored. Parthenolide is a sesquiterpene lactone with promising
antitumor effects against TNBC cell lines. This review highlights the importance of parthenolide
and its analogue drugs in TNBC treatment.
Keywords: Parthenolide, triple negative breast cancer, sesquiterpene lactones, nuclear factor-κB, heterogeneity, natural products.
Rights & PermissionsPrintExport